OverT Bio is a New York City-based biotechnology company founded in 2022 by Dr. Mat Legut and Dr. Neville Sanjana. Specializing in cell therapies for solid tumors, the company utilizes data-driven approaches combining cell engineering and big data analytics. With its recent activities focused on pioneering therapies, OverT Bio has successfully raised $16 million in seed funding. Their unique platforms, OverTarget™ and OverTCR™, reflect their commitment to innovative cancer treatment.
May 2024: OverT Bio successfully secured $16 million in seed funding. The funding is intended to advance their proprietary platforms, OverTarget™ and OverTCR™, aimed at developing next-generation engineered immune cells. This investment highlights the growing interest in OverT Bio's approach to treating solid tumors through innovative cell engineering strategies.
May 2023: OverT Bio announced its foundational goal of transforming cell therapy in solid tumors utilizing synthetic biology techniques. These developments allow for superior efficacy in cancer treatment by harnessing a patient’s innate immune response to identify novel cancer targets.
OverT Bio continued to develop its technology suite incorporating parallel genetic screening and single-cell multiomics, enhancing their advancements in cell therapy as a powerful treatment for cancer patients.
| Attribute | Information |
|---|---|
| Founding Date | 2022 |
| Headquarters | New York City, USA |
| Founders | Dr. Mat Legut, Dr. Neville Sanjana |
| Revenue | N/A |
| Profits | N/A |
| Key Investors | N/A |
| Industry | Biotechnology |
| Number of Employees | N/A |
OverT Bio was conceived with a vision to revolutionize cell therapy for solid cancer tumors. Established in 2022, the company was the brainchild of Dr. Mat Legut and Dr. Neville Sanjana, both of whom have profound expertise in cell therapy and immunology. The genesis of OverT Bio is deeply rooted in their shared commitment to overcoming limitations in existing cancer therapies, focusing on synthetic biology and genetic screening innovations. The initial phase of OverT Bio's journey was marked by intensive research and development activities, establishing essential partnerships, and setting the foundation for their cutting-edge platforms, OverTarget™ and OverTCR™.
OverT Bio's business model leverages the intersection of synthetic biology and big data to innovate within the cell therapy domain, focusing primarily on solid tumors.
Currently, OverT Bio operates within a niche yet burgeoning field of biotechnology dedicated to treating solid tumors through innovative cell therapy solutions. Their unique approach, which integrates synthetic biology with the understanding of patient-specific immune mechanisms, distinguishes OverT Bio in the competitive biotech market. While still in its early stages of funding and growth, the company's platforms promise substantial therapeutic advancements. OverT Bio's competitive edge lies in its capacity to translate complex scientific research into tangible treatment solutions with high efficacy and patient-specific adaptability.
OverT Bio represents a pivotal force in the biotechnology sector, particularly in the realm of cell therapies for solid tumors. With its foundation in cutting-edge science and innovation, supported by robust seed funding, the company is well-poised to make significant contributions to cancer treatment. Looking ahead, OverT Bio's advancements in personalized cell therapy are expected to redefine therapeutic strategies, addressing unmet medical needs in oncology. The company’s unique integration of synthetic biology and data analytics to develop engineered immune cells positions it as a promising leader in transforming cancer treatment paradigms.